CL
CLLS.US Cellectis SA
- Market cap
- USD 119M
- P/E
- -
- P/B
- 3.39x
- ROE
- -192.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CLLS.US undervalued?
Graham numberThe Graham number of Cellectis SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cellectis SA fundamental analysis
No fundamental analysis for Cellectis SA yet.
Cellectis SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, ex…
Full company profileCellectis SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cellectis SA annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 42.6M | 25.2M | 12.7M | 15.2M | 73.9M | 73.9M | 19.2M | 755K | 41.5M | 72.9M | 22.0M |
| Gross Profit | 40.9M | 22.6M | 9.99M | 3.80M | 37.7M | 37.7M | 17.4M | -6.66M | 32.3M | 63.2M | 4.12M |
| Operating Income | -64.0M | -92.7M | -105M | -124M | -85.4M | -85.4M | -89.7M | -97.3M | -59.6M | -33.1M | -105M |
| EBITDA | -65.0M | -108M | -103M | -117M | -75.6M | -68.9M | -71.2M | -92.6M | -9.46M | -39.8M | -87.2M |
| Net Income | -63.9M | -99.4M | -78.7M | -90.7M | -72.6M | -86.3M | -98.7M | -101M | -36.8M | -67.6M | -79.2M |
| EPS | -1.78 | -2.78 | -1.93 | -2.14 | -1.71 | -2.03 | -2.17 | -1.77 | -0.41 | -0.67 | -0.79 |
| Balance Sheet | |||||||||||
| Total Assets | 331M | 333M | 501M | 467M | 469M | 382M | 261M | 334M | 384M | 325M | 267M |
| Total Liabilities | 56.6M | 47.0M | 50.6M | 112M | 161M | 146M | 135M | 250M | 253M | 249M | 226M |
| Shareholders' Equity | 274M | 267M | 409M | 315M | 284M | 221M | 118M | 84.7M | 131M | 75.9M | 41.1M |
| Cash & Short-term Investments | 290M | 297M | 452M | 361M | 268M | 186M | 97.7M | 204M | 260M | 209M | 167M |
| Total Debt | 1.76M | 34.0K | 1.35M | 47.6M | 107M | 101M | 75.8M | 85.1M | 91.5M | 120M | 84.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -31.1M | -52.3M | -68.1M | -69.1M | -80.3M | -105M | -87.4M | -24.7M | 22.1M | -40.1M | -59.7M |
| Capital Expenditure | 13.3M | 2.66M | 4.89M | 13.0M | 44.4M | 18.6M | 2.44M | 1.07M | 2.58M | 2.37M | 1.04M |
| Free Cash Flow | -44.4M | -55.0M | -73.0M | -82.1M | -125M | -123M | -89.9M | -25.8M | 19.5M | -42.5M | -60.7M |
| Ratios | |||||||||||
| ROE | -23.3% | -37.2% | -19.2% | -28.8% | -25.6% | -39.0% | -83.7% | -119.3% | -28.1% | -89.1% | -192.9% |
| ROA | -19.3% | -29.9% | -15.7% | -19.4% | -15.5% | -22.6% | -37.8% | -30.2% | -9.6% | -20.8% | -29.6% |
| Net Profit Margin | -150.1% | -394.5% | -618.1% | -597.0% | -98.1% | -116.7% | -514.8% | -13,385.3% | -88.6% | -92.7% | -359.5% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.15x | 0.38x | 0.46x | 0.64x | 1.00x | 0.70x | 1.58x | 2.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cellectis SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 569K | 0.01 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cellectis SA
- Insiders 0.00%
- Institutions 13.45%
- Public & others 86.55%
- Shares outstanding 72.7M
- Free float 48.6M
Top funds holding CLLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 724K | 0.72% | -6.04% | Jul 2026 |
| iShares Biotechnology ETF | 246K | 0.24% | -0.19% | Oct 2026 |
| Nomura Healthcare Fund Class I | 227K | 0.23% | 0.00% | Sep 2026 |
| Galileo - Biotech Innovation Fund S USD | 226K | 0.22% | 0.00% | Apr 2026 |
| Ox Capital Dynamic Asia N USD Unhdgd Acc | 95.3K | 0.09% | 0.00% | Jan 2026 |
| Prisma Cube | 30.0K | 0.03% | 0.00% | Jun 2026 |
| P & S Renditefonds T | 15.0K | 0.01% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 1.95K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding CLLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| B Group, Inc | 3.28M | 3.26% | 0.00% | Jun 2026 |
| Long Focus Capital Management, LLC | 2.74M | 2.72% | -0.08% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 2.64M | 2.63% | -16.79% | Jun 2026 |
| Delaware Management Holdings Inc | 227K | 0.23% | 0.00% | Jun 2026 |
| BlackRock Inc | 225K | 0.22% | -33.99% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 85.5K | 0.08% | -1.52% | Jun 2026 |
| LPL Financial Corp | 84.4K | 0.08% | +0.08% | Jun 2026 |
| Susquehanna International Group, LLP | 50.5K | 0.05% | -23.49% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 40.1K | 0.04% | -2.20% | Jun 2026 |
| Walleye Partners, LLC | 35.0K | 0.03% | 0.00% | Sep 2026 |
| UBS Group AG | 33.9K | 0.03% | +13.95% | Jun 2026 |
| Delaney Dennis R | 24.0K | 0.02% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 14.3K | 0.01% | -5.02% | Jun 2026 |
| XTX Topco Ltd | 12.3K | 0.01% | -24.51% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 4.50K | 0.00% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 3.60K | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 3.15K | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 1.56K | 0.00% | 0.00% | Jun 2026 |
| Atlantic Union Bankshares Corp | 1.50K | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 500.00 | 0.00% | 0.00% | Jun 2026 |
Cellectis SA company profile
- Company name
- Cellectis SA
- Ticker
- CLLS.US
- Exchange
- USA Stocks
- Listed since
- Feb 7, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 224
- Fiscal year end
- December
- Address
- 8, rue de la Croix Jarry, Paris, France, 75013
- Phone
- 33 1 81 69 16 00
- Website
- cellectis.com
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis SA management
10- Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director · born 1965
- Dr. David J. Sourdive Ph.D.Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director · born 1967
- Mr. Arthur StrilCFO & Chief Business Officer · born 1989
- Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
- Mr. Jean Charles Epinat Ph.D.Chief Technological Officer
- Dr. Philippe Duchateau Ph.D.Chief Scientific Officer · born 1963
- Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors · born 1982
- Pascalyne WilsonDirector of Communications
- Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer · born 1970
- Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance Officer · born 1969